FORM 6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of July 2021
Commission
File Number: 001-11960
AstraZeneca PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge
CB2 0AA
United
Kingdom
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ______
Indicate
by check mark whether the registrant by furnishing the information
contained in this Form is also thereby furnishing the information
to the Commission pursuant to Rule 12g3-2(b) under the Securities
Exchange Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number
assigned to the Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca PLC
INDEX
TO EXHIBITS
1.
Director/PDMR
Shareholding
21 July 2021 15:50 BST
Transaction by Person Discharging Managerial
Responsibilities
AstraZeneca PLC (the Company) announced that on 21 July 2021, Marc
Dunoyer, Chief Financial Officer, received 21,243 Ordinary
Shares of $0.25 each in the Company (Ordinary Shares). The Ordinary
Shares were issued to Mr Dunoyer on completion of the Company's
acquisition of Alexion Pharmaceuticals, Inc. (Alexion) as part
consideration for the 20,000 Alexion shares held by Mr Dunoyer at
the time of completion.
In accordance with the Agreement and Plan of Merger entered into by
the Company on 12 December 2020, as consideration for each Alexion
share held on completion of the acquisition, being 21 July 2021,
Alexion shareholders received $60 in cash and, at their election,
either 2.1243 AstraZeneca American Depositary Shares (each
representing one half of an Ordinary Share) or the Ordinary Share
equivalent.
PDMR
|
Nature of the transaction
|
Quantity of Ordinary Shares received
|
Estimated valuation of price per Ordinary Share
|
Marc Dunoyer
|
Ordinary
Shares issued in consideration for the acquisition of Alexion
Pharmaceuticals, Inc.
|
21,243
|
US$115.08
|
The attached notification, made in accordance with the requirements
of the EU and UK Market Abuse Regulations, gives further
detail.
1
|
Details of the person discharging managerial responsibilities /
person closely associated
|
a)
|
Name
|
Marc Dunoyer
|
2
|
Reason for the notification
|
a)
|
Position/status
|
Chief Financial Officer
|
b)
|
Initial notification /Amendment
|
Initial notification
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
a)
|
Name
|
AstraZeneca PLC
|
b)
|
LEI
|
PY6ZZQWO2IZFZC3IOL08
|
4
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted
|
a)
|
Description of the financial instrument, type of
instrument
Identification code
|
Ordinary Shares of US$0.25 each in AstraZeneca PLC
GB0009895292
|
b)
|
Nature of the transaction
|
Ordinary Shares issued in consideration for the acquisition of
Alexion Pharmaceuticals, Inc.
|
c)
|
Price(s) and volume(s)
|
Price(s)*
|
Volume(s)
|
US$115.08
|
21,243
|
*non-cash consideration: price is an estimated
valuation
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
Not applicable - single transaction
|
e)
|
Date of the transaction
|
21 July 2021
|
f)
|
Place of the transaction
|
Outside a trading venue
|
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led
biopharmaceutical company that focuses on the discovery,
development and commercialisation of prescription medicines in
Oncology, Rare Diseases and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over
100 countries, and its innovative medicines are used by millions of
patients worldwide. Please visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please
click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
Date:
21 July 2021
|
By: /s/
Adrian Kemp
|
|
Name:
Adrian Kemp
|
|
Title:
Company Secretary
|